Published in Front Oncol on December 30, 2013
Thyroid hormone and P-glycoprotein in tumor cells. Biomed Res Int (2015) 0.81
Editorial: multidrug resistance in cancer: pharmacological strategies from basic research to clinical issues. Front Oncol (2015) 0.77
Nedaplatin sensitization of cisplatin-resistant human non-small cell lung cancer cells. Oncol Lett (2016) 0.75
Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer (2002) 15.72
Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol (2009) 13.01
Rab11 regulates recycling through the pericentriolar recycling endosome. J Cell Biol (1996) 9.27
Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A (1987) 7.38
The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem (1989) 7.13
Rab7: a key to lysosome biogenesis. Mol Biol Cell (2000) 6.42
Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell (1994) 6.02
Role of Rab GTPases in membrane traffic and cell physiology. Physiol Rev (2011) 5.20
Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A (1989) 4.66
Rab 7: an important regulator of late endocytic membrane traffic. J Cell Biol (1995) 4.23
Complete polarization of single intestinal epithelial cells upon activation of LKB1 by STRAD. Cell (2004) 3.87
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci U S A (1997) 3.20
Signals from the lysosome: a control centre for cellular clearance and energy metabolism. Nat Rev Mol Cell Biol (2013) 3.13
Visualization of Rab9-mediated vesicle transport from endosomes to the trans-Golgi in living cells. J Cell Biol (2002) 3.03
Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci (2000) 2.81
Post-Golgi biosynthetic trafficking. J Cell Sci (1997) 2.62
Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control (2003) 2.46
P-glycoprotein and multidrug resistance. Curr Opin Genet Dev (1996) 2.33
Rab6 regulates transport and targeting of exocytotic carriers. Dev Cell (2007) 2.32
Endocytic trafficking routes of wild type and DeltaF508 cystic fibrosis transmembrane conductance regulator. Mol Biol Cell (2004) 2.21
Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets (2006) 1.96
Myosin II is involved in the production of constitutive transport vesicles from the TGN. J Cell Biol (1997) 1.78
Rescue of ΔF508-CFTR trafficking via a GRASP-dependent unconventional secretion pathway. Cell (2011) 1.72
Multidrug resistance transporters and modulation. Curr Opin Oncol (2000) 1.71
The Rip11/Rab11-FIP5 and kinesin II complex regulates endocytic protein recycling. J Cell Sci (2008) 1.64
Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma. Leuk Lymphoma (2007) 1.58
Rab11a and myosin Vb are required for bile canalicular formation in WIF-B9 cells. Proc Natl Acad Sci U S A (2005) 1.53
Three decades of P-gp inhibitors: skimming through several generations and scaffolds. Curr Med Chem (2012) 1.45
Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther (2000) 1.44
Rab11b regulates the apical recycling of the cystic fibrosis transmembrane conductance regulator in polarized intestinal epithelial cells. Mol Biol Cell (2009) 1.41
Transporters on demand: intrahepatic pools of canalicular ATP binding cassette transporters in rat liver. J Biol Chem (2000) 1.37
Endocytic trafficking of CFTR in health and disease. J Cyst Fibros (2006) 1.36
Coordination between RAB GTPase and phosphoinositide regulation and functions. Nat Rev Mol Cell Biol (2012) 1.35
N-Linked glycosylation of the human ABC transporter ABCG2 on asparagine 596 is not essential for expression, transport activity, or trafficking to the plasma membrane. Biochemistry (2005) 1.33
Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. Expert Opin Drug Metab Toxicol (2008) 1.32
Rab13 regulates membrane trafficking between TGN and recycling endosomes in polarized epithelial cells. J Cell Biol (2008) 1.30
ER exit sites--localization and control of COPII vesicle formation. FEBS Lett (2009) 1.25
A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Clin Cancer Res (2007) 1.24
Newly synthesized canalicular ABC transporters are directly targeted from the Golgi to the hepatocyte apical domain in rat liver. J Biol Chem (2000) 1.23
P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res (1999) 1.14
The human multidrug resistance P-glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy. FASEB J (1999) 1.08
Bile acid secretion and direct targeting of mdr1-green fluorescent protein from Golgi to the canalicular membrane in polarized WIF-B cells. J Cell Sci (1999) 1.07
Actin disruption inhibits endosomal traffic of P-glycoprotein-EGFP and resistance to daunorubicin accumulation. Am J Physiol Cell Physiol (2006) 1.06
Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells. Biochem Pharmacol (2006) 1.04
P-glycoprotein stability is affected by serum deprivation and high cell density in multidrug-resistant cells. J Cell Physiol (1995) 1.02
SPTLC1 binds ABCA1 to negatively regulate trafficking and cholesterol efflux activity of the transporter. Biochemistry (2008) 1.01
Experimentally induced changes in the endocytic traffic of P-glycoprotein alter drug resistance of cancer cells. Am J Physiol (1997) 0.98
A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar). Cancer (2001) 0.98
Disulfide bonds and protein folding Biochemistry (2000) 0.97
Intracellular trafficking of P-glycoprotein. Int J Biochem Cell Biol (2011) 0.96
Dynamic and intracellular trafficking of P-glycoprotein-EGFP fusion protein: Implications in multidrug resistance in cancer. Int J Cancer (2004) 0.95
Role of multiple drug resistance protein 1 in neutral but not acidic glycosphingolipid biosynthesis. J Biol Chem (2003) 0.95
Conserved intramolecular disulfide bond is critical to trafficking and fate of ATP-binding cassette (ABC) transporters ABCB6 and sulfonylurea receptor 1 (SUR1)/ABCC8. J Biol Chem (2011) 0.95
The ER glycoprotein quality control system. Curr Issues Mol Biol (2004) 0.92
P-glycoprotein expression in the Golgi apparatus of multidrug-resistant cells. Int J Cancer (1994) 0.91
FBXO15 regulates P-glycoprotein/ABCB1 expression through the ubiquitin--proteasome pathway in cancer cells. Cancer Sci (2013) 0.89
P-Glycoprotein is not present in mitochondrial membranes. Exp Cell Res (2007) 0.89
Coordinated elevation of mitochondrial oxidative phosphorylation and autophagy help drive hepatocyte polarization. Proc Natl Acad Sci U S A (2013) 0.89
The ABCA1 Q597R mutant undergoes trafficking from the ER upon ER stress. Biochem Biophys Res Commun (2008) 0.88
TBC1D13 is a RAB35 specific GAP that plays an important role in GLUT4 trafficking in adipocytes. Traffic (2012) 0.86
Rab4 interacts with the human P-glycoprotein and modulates its surface expression in multidrug resistant K562 cells. Int J Cancer (2011) 0.81
The small GTPases Rab5 and RalA regulate intracellular traffic of P-glycoprotein. Biochim Biophys Acta (2007) 0.80